FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection – Pharmaceutical Technology
Concerns over Jiangsu’s facilities come ahead of the US’s preparations to launch the BIOSECURE Act. Credit: grandbrothers via Shutterstock. The US Food and Drug Administration